Spinal Myeloid Sarcoma in Two Non-Leukemic Patients

Songul Serefhanoglu, Hakan Goker, Salih Aksu, Yahya Buyukasik, Nilgun Sayinalp, Ibrahim Celalettin Haznedaroğlu and Osman Ilhami Ozcebe

Abstract

Myeloid sarcoma, formerly termed granulocytic sarcoma or chloroma, consists of neoplastic granulocytic precursors and myeloblasts. Isolated chloromas (granulocytic sarcomas) are rare tumors. Spinal complications of chloromas, such as cord compression secondary to epidural tumor or cauda equine syndrome have been described but are rare. We herein report two cases with spinal granulocytic sarcomas in non-leukemic patients. The case of a previously healthy 22-year-old man diagnosed with multiple spinal granulocytic sarcomas with no evidence of bone marrow or other hematological involvement is described. And, a 43-year-old woman diagnosed cervical spinal granulocytic sarcoma with no evidence of bone marrow or other hematological involvement is described. The tumor was totally removed by microsurgery. The histopathological examination was consistent with granulocytic sarcoma. Granulocytic sarcoma should be considered in the differential diagnosis of an epidural mass in patients with or without acute leukemia, because early diagnosis followed by appropriate combined chemotherapy and radiation may obviate surgical intervention and eventually prevent leukemic transformation.

Key words: myeloid sarcoma, spinal cord compression

(Intern Med 49: 2493-2497, 2010)
(DOI: 10.2169/internalmedicine.49.3878)

Introduction

Myeloid sarcoma (granulocytic sarcoma) has been defined as a tumor mass consisting of myeloid blasts with or without maturation occurring at an anatomical site other than the bone marrow. Myeloid sarcomas are malignant neoplasms with the formation of invasive and destructive localized masses (1). Almost every site of the body can be involved; the skin, lymph node, gastrointestinal tract, bone, soft tissue and testis being more frequently affected. Two sites commonly involved with myeloid sarcoma are skin and lymph nodes (2, 3). Multiple anatomical sites constitute less than 10% of myeloid sarcoma cases. Myeloid sarcoma may occur de novo or as the initial manifestation of relapse in a patient with previously diagnosed acute myeloid leukemia without blood or bone marrow findings. Myeloid sarcoma develops in 2-8% of patients with acute myeloid leukemia (4, 5). Myeloid sarcomas involving the spinal cord and brain in patients without myeloid leukemia are rare. Spinal involvements are frequently misdiagnoses, usually as malignant lymphomas (2). In a review of the literature in 2002, Yamauchi and Yasuda found that 35 (47%) of 74 patients initially were misdiagnosed (non-Hodgkin lymphoma, lymphosarcoma, histiocytic lymphoma, reticulum cell sarcoma, lymphocytic sarcoma, thymoma, myeloma, eosinophilic sarcoma and carcinoma). Eosinophilia of more than 300/μL was observed in 7/29 (24%) of patients assessed for the blood leukocyte differentials and 22/31 (73%) of patients had infiltration of eosinophilic infiltrate in the tumor. An inversion of chromosome 16 that may be associated with eosinophilia and eosinophil infiltration in granulocytic sarcoma tumor was not reported in these patients (6). Although eosinophilia and eosinophil infiltration in the tumor also occurs frequently in patients with granulocytic sarcoma, the inversion was not found in that review. Nonleukemic myeloid sarcoma patients may eventually develop acute leukemia (2, 7). Myeloid sarcomas of the spine and brain are usually located extradurally and associated with or lack bone involvement with or without bone destruction. The diagnosis of myeloid sarcoma of the spine and brain and its treatment has a very poor prognosis. We report two cases...
he died due to septic shock. However, the patient’s condition worsened and demonstrated a decreased maximum SUV of 3. How-
ever, the patient’s condition worsened and she died due to ventricular fibrillation and cardiac arrest.

Case 2

A previously healthy 43-year-old woman presented with left arm and leg pain that had worsened over a period of 3-4
months. No symptoms of paralysis were observed. She de-
nied motor weakness and bowel or bladder incontinence. Magnetic resonance imaging showed an epidural 1.5 cm
mass at the cervical spine (C6-7 level). Fluorodeoxyglucose (FDG) positron-emission tomography (PET) scan indicated
that the lesion had a maximum standardized uptake value [SUV (max)] of 7. The patient underwent laminectomy of
the cervical spine (C6-7 level) and the tumor was removed. The complete blood count and coagulation tests were nor-
mal, and no sign of leukemia was observed in the peripheral blood and bone marrow. Histological examination demon-
strated fibroadipose connective tissue including diffuse cellular
infiltrates. The great majority of the cells in the infiltrate consisted of myeloid precursors with large round to oval
cells with slightly eosinophilic cytoplasm and round to oval vesicular nuclei, admixed with a minor population of more
mature myeloid forms including eosinophils. Immunohisto-
chemical stains showed tumor cells positive for myeloperox-
adise (MPO) and negative for CD 3, 5, 7, 10, 12, 23 and
Tdt. Mitotic figures were abundant. In consequence of this
finding, the tumor was diagnosed as non-leukemic granulo-
cytic sarcoma. Cytogenetic study of the bone marrow cells revealed a normal karyotype (46.XX (25)). Molecular analy-

Discussion

Granulocytic sarcoma, also termed myeloid sarcoma or chloroma (King used ‘chloroma’ as the first term to describe
this condition in 1853 (10)), is a rare malignant neoplasm resulting from the extramedullary proliferation of myeloid
blasts with or without maturation or immature myeloid cells, which is reported frequently in acute myeloid leukemia,
myelodysplastic syndromes with leukemic transformation, chronic myeloid leukemia with blastic crisis or in non-
leukemic patients (8, 9). Granulocytic sarcoma is more than twice as common in children as in adults with acute
myeloid leukemia and its overall incidence is 2.5-8% (5, 11, 12). Its prognosis is poor and most patients die
within months. The WHO has renamed the condition as myeloid sarcoma and divided it into two major categories,
Chloromas usually present as soft tissue or bony masses of the head and neck in patients with acute myeloblastic leukemia (AML) of the French-American-British M2 subtype. Granulocytic sarcoma rarely presents in the absence of systemic myeloid disease (14, 15). Moreover, 66-88% of patients with an isolated granulocytic sarcoma will develop AML at a mean of 9-11 months after diagnosis (16). Granulocytic sarcoma most commonly occurs in the soft tissues of the skin and bone, soft tissue of the head and neck (frequently the orbits), lymph node; rare cases involve the heart or small intestines and less often in the central nervous system and spinal cord (17-19). Involvement of the central nervous system (CNS) is rare, and spinal cord compression by granulocytic sarcoma is even more rare (8, 9).

Although involvement of every organ system has been reported in granulocytic sarcoma, the most common site is bone. The correct diagnosis of granulocytic sarcoma is obtained in only about 50% of non-leukemic patients due to its rareness and the histological and radiological similarities to malignant lymphoma (20). Well-differentiated myeloid sarcomas are composed of eosinophilic myelocytes (21). The characteristic myeloid sarcoma phenotype is CD45, CD43, CD68 and myeloperoxidase positive and CD20 and CD45RO negative (21, 22). Myeloperoxidase, CD15 and neutrophil elastase are especially effective to differentiate granulocytic sarcoma from other tumors. Patients with non-leukemic granulocytic sarcoma may eventually develop...
acute leukemia (2, 7). Chromosome 8 abnormalities were the dominant abnormalities in the bone marrow and/or extramedullary sites. Translocation between chromosomes 8 and 21 is common in granulocytic sarcoma but not requisite.

In MD Anderson Cancer Center data, granulocytic sarcoma occurred in 1.4% of patients with AML, and in 1.1% of patients with AML or high-risk myelodysplastic syndromes (MDS) (23). The median overall survival was 20 months (range, 1-75), median overall failure-free survival was 12 months (range, 1-75). The median survival of patients with chromosome 8 abnormalities was 12 months compared to 40 months in those without (p=0.17) (23). In a literature review, the affected sites included cervical, thoracic, lumbar, sacral spinal level, bilateral renal enlargement, brain mass and cerebellum in non-leukemic patients. The thoracic spine was most commonly involved followed by the lumbar, sacral and cervical regions. The important clinical findings included pain (especially back pain), paresis, bowel or bladder incontinence, motor deficits, hypoesthesia, convulsions, cranial nerve palsies, papilloedema, cerebellar deficits, hemiparesis, aphasia, radicular pain, numbness and weakness of the extremities. Histological examination demonstrated neoplastic cells with small round and hyperchromatic nuclei proliferating in a diffuse pattern, and immature granulocytic cells and immunohistochemical staining demonstrated positive for myeloperoxidase (MPO), CD15, CD33, D56, CD34, CD45, LCA, chloroacetate esterase, monocytic antigen CD68, leukocyte common antigen CD45, neutrophil elastase and lysosome but negative for Tdt, CD20. The lesions were commonly isodense or hyperdense with surrounding edema on pre-contrast CT and they were markedly enhanced after contrast injection. The patients treated with surgical decompression, received additional AML type chemotherapy, radiotherapy, or bone marrow transplantation. Tsimberidou et al compared the clinical outcomes of matching granulocytic sarcoma patients with analogous AML patients in the MD Anderson Cancer Center (n=23 granulocytic sarcomas, n=1,720 AML patients). Complete response rates were 69% in patients with granulocytic sarcomas and 57% in patients with AML. The 2-year event-free survival (EFS) and overall survival (OS) rates were 32% and 18% (p=0.08) and 43% and 29% (p=0.11), respectively. They suggested that anti-AML therapy was highly effective in patients with nonleukemic granulocytic sarcomas and granulocytic sarcoma was associated with superior event-free survival and overall survival compared with acute myeloid leukemia (24-28).

Persisting eosinophilia occurs in hematologic malignancies such as idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, systemic mast cell disease, chronic myeloid leukemia, chronic myeloproliferative disorders other than chronic myeloid leukemia and chronic myelomonocytic leukemia (29). Chromosomal abnormalities in eosinophilia-associated hematological disease include chromosome bands 5q31-35 and 8p117, deletions of 20q, trisomy 8, and monosomy 7 (30). Chronic eosinophilic leukemia with trisomy 8 has been reported to be associated with transformation into acute leukemia and granulocytic sarcoma in the literature. Fuji et al reported a patient with hypereosinophilic syndrome, which, 8 years later, transformed into granulocytic sarcoma in the brain and, subsequently, into acute myelocytic leukemia. Trisomy 8 was demonstrated in cells from the bone marrow and cerebrospinal fluid (31). Guitard et al demonstrated a pediatric case of hypereosinophilic syndrome with trisomy 8 and terminal blast transformation to mixed acute leukemia (32). WHO classification chronic eosinophilic leukemia is defined by an increase of >2% blasts in the peripheral blood or of >5-19% in bone marrow or evidence of clonality (33). In the present study, case 1 presented with eosinophilia with no blast in peripheral smear and bone marrow. Other potential causes of the eosinophilia were excluded.

Spinal complications of chloromas, such as cord compression secondary to epidural tumor or cauda equine syndrome have been described but are rare. The current two patients presented with spinal epidural tumors which caused spinal cord and cauda equine compression. Case 1, presented with eosinophilia and had multiple site myeloid sarcomas. Case 2, presented isolated cervical spinal granulocytic sarcoma. There was no leukemic involvement in bone marrow of two patients. The optimal therapy for patients with non-leukemic granulocytic sarcoma has not been determined. Our data indicated that AML-type intensive chemotherapy with or without radiotherapy was moderately effective. In conclusion, prompt diagnosis and adequate treatment are essential to achieve a good outcome.

References

1853.